세계 다발성 골수종 치료제 시장 규모는 2024년 234억 6,000만 달러에 달했습니다. 향후 IMARC Group은 2033년에는 368억 6,000만 달러에 달할 것으로 예상되며, 2025-2033년간 4.89%의 CAGR을 기록할 것으로 예측하고 있습니다. 현재 북미가 시장을 독점하고 있으며, 2024년에는 40.7% 이상의 큰 시장 점유율을 차지했습니다. 이러한 우위는 첨단 의료 인프라, 혁신적인 치료법의 높은 채택률, 종양학 연구에 대한 막대한 투자에 기인합니다. 주요 제약사의 존재와 유리한 상환 정책은 이 지역의 다발성 골수종 치료제 시장 점유율을 더욱 높이고 있습니다.
정밀 의료 접근 방식과 바이오마커 기반 치료 전략이 급증하면서 시장을 견인하고 있습니다. 이중특이성항체 및 차세대 프로테아좀 억제제를 포함한 신약개발에 대한 제약사들의 투자가 증가하면서 치료 선택의 폭이 넓어지고 있습니다. 전 세계 각 지역의 임상시험 설계 강화와 적응형 규제 경로를 통해 혁신 의약품의 시장 출시 시간이 단축되고 있습니다. 또한, 영상 진단과 유전체학의 발전으로 질병 분류가 정교해져 보다 맞춤화된 치료 요법이 가능해졌습니다. 환자의 반응을 모니터링하고 순응도를 높이기 위한 디지털 헬스 기술의 도입이 진행되고 있는 것도 중요한 역할을 하고 있습니다. 생명공학 기업과 연구기관의 전략적 제휴는 현재 진행 중인 치료법의 발전을 더욱 촉진하고 있습니다.
미국에서는 종양학 연구를 위한 연방 정부의 적극적인 자금 지원과 선진화된 의료 인프라가 시장 성장을 주도하고 있습니다. CAR-T 세포 치료제, 항체약물접합체 등 획기적인 치료법의 채택률이 높아 시장 침투가 가속화되고 있습니다. 강력한 상업화 역량을 갖춘 대형 제약사의 존재가 신속한 약물 개발을 뒷받침하고 있습니다. 또한, 메디케어와 민간 보험사를 통한 유리한 상환 프레임워크가 고가의 치료에 대한 접근성을 향상시키고 있습니다. 고령화와 평균수명의 증가도 질병 발생률 상승에 기여하고 있습니다. 예를 들어, 2025년 5월 ADVANCE 시험에서 다라투무맙을 포함한 4제 병용요법(DKRd)이 새로 다발성 골수종 진단을 받은 환자들의 예후를 개선한 것으로 나타났습니다. 표준 KRd 요법과 비교했을 때, DKRd는 독성을 유의하게 증가시키지 않으면서 MRD 음성률이 더 높고(59% 대 36%), 무진행 생존기간이 약 33개월(86% 대 79%)로 개선되었습니다. 이러한 결과는 DKRd가 새로운 표준치료가 될 가능성을 지지하며, 일부 환자들은 줄기세포 이식을 연기할 수 있게 되었고, 치료방침 결정에 있어 MRD 음성의 중요성을 강조하였습니다.
혈액암 부담 증가로 약품 수요 급증
전 세계적으로 혈액 악성종양 발병률이 증가하면서 다발성 골수종 치료제 시장에 큰 영향을 미치고 있습니다. 2022년, 이러한 암은 전체 암 진단 환자의 6.6%, 관련 사망의 7.2%를 차지할 것으로 예상되며, 표적치료에 대한 심각한 필요성이 대두되고 있습니다. 다발성 골수종은 주로 유전자 이상에 기인하기 때문에 치료에는 면역조절제, 화학요법, 방사선치료, 줄기세포 이식 등 다학제적 접근이 필요합니다. 혈소판 수혈도 부작용을 관리하는 역할을 합니다. 조기 발견이 개선되어 더 많은 환자들이 고급 치료를 받을 수 있게 되었습니다. 전 세계 의료 시스템은 효과적인 치료법을 제공해야 할 필요성에 직면해 있으며, 이는 기술 혁신을 가속화하고 골수종에 특화된 약물에 대한 투자를 촉진하고 있어 다발성 골수종 치료제 시장의 전망은 밝습니다.
치료 혁신을 가속화하는 기술 발전
기술의 발전은 특히 마이크로 RNA 기반 치료와 나노 의약품과 같은 혁신을 통해 다발성 골수종 치료제에 변화를 가져오고 있습니다. 이러한 플랫폼은 정상 조직의 손상을 최소화하면서 악성 세포를 정밀하게 표적화할 수 있습니다. 대표적으로 네덜란드 오스(Oss)에 위치한 아르데나(Aldena)의 나노메디슨 시설은 2,000만 유로를 투자하여 2024년 11월에 GMP 인증을 획득했습니다. 이 시설은 고분자 약물을 골수로 운반하고 항종양 반응을 일으키는 중요한 전달 수단인 지질과 고분자 나노입자의 복잡한 제조를 지원합니다. 이러한 기술 혁신은 치료 결과를 향상시킬 뿐만 아니라 합병증을 줄여 장기적인 의료 비용을 절감할 수 있습니다. 제약회사들이 나노기술 역량을 확대함에 따라 이러한 개발은 다발성 골수종 치료제 시장의 성장을 촉진하는 데 중요한 역할을 할 것으로 예상됩니다.
생물학적 치료법 채택과 의료비 지출 증가
생물학적 제제에 대한 인식이 높아지면서 다발성 골수종에 대한 치료 선호도가 변화하고 있습니다. 생물학적 제제는 면역체계를 활용하여 암세포를 인식하고 제거하는 것으로, 기존 치료법보다 침습성이 낮고, 많은 경우 더 효과적인 대체요법이라고 할 수 있습니다. 환자들은 전신 부작용이 적고 표적화된 메커니즘을 제공하는 치료법에 점점 더 매력을 느끼고 있습니다. 이러한 추세와 함께 2021년 세계 GDP의 10.3%에 해당하는 9조 8,000억 달러에 달하는 세계 의료비 지출 증가는 이러한 첨단 치료에 대한 폭넓은 접근을 가능하게 하고 있습니다. 제약 업계의 연구 예산 확대와 함께 생물학적 제제는 선진국 시장과 신흥국 시장 모두에서 인기를 끌고 있습니다. 이러한 변화는 향후 수년간 다발성 골수종 치료제 시장 확대에 크게 기여할 것으로 예상됩니다.
The global multiple myeloma drugs market size was valued at USD 23.46 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 36.86 Billion by 2033, exhibiting a CAGR of 4.89% during 2025-2033. North America currently dominates the market, holding a significant market share of over 40.7% in 2024. This dominance is driven by advanced healthcare infrastructure, high adoption of innovative therapies, and substantial investment in oncology research. The presence of key pharmaceutical companies and favorable reimbursement policies further fuel multiple myeloma drugs market share in the region.
The market is propelled by an upsurge in precision medicine approaches and biomarker-driven treatment strategies. Increasing investments by pharmaceutical companies in novel drug discovery, including bispecific antibodies and next-generation proteasome inhibitors, are expanding therapeutic options. Enhanced clinical trial designs and adaptive regulatory pathways in global regions are accelerating time-to-market for innovative drugs. Moreover, improvements in diagnostic imaging and genomics have refined disease classification, enabling more personalized treatment regimens. The growing incorporation of digital health technologies to monitor patient response and improve adherence also plays a significant role. Strategic collaborations among biotech firms and research institutions further support ongoing therapeutic advancements.
In the United States, the multiple myeloma drugs market growth is driven by robust federal funding for oncology research and the presence of an advanced healthcare infrastructure. The high adoption rate of breakthrough therapies, including CAR-T cell therapies and antibody-drug conjugates, is accelerating market penetration. The presence of major pharmaceutical players with strong commercialization capabilities supports rapid drug deployment. Additionally, favorable reimbursement frameworks through Medicare and private insurers improve access to costly treatments. An aging population and increasing life expectancy also contribute to rising disease incidence. For instance, in May 2025, a four-drug combination (DKRd) including daratumumab showed improved outcomes for newly diagnosed multiple myeloma patients in the ADVANCE trial. Compared to the standard KRd regimen, DKRd achieved higher MRD-negativity (59% vs. 36%) and better progression-free survival at nearly 33 months (86% vs. 79%), without significantly increased toxicity. These findings support DKRd as a potential new standard of care, enabling some patients to defer stem cell transplants and highlighting the importance of MRD-negativity in guiding treatment decisions.
Rising Burden of Hematological Cancers Boosting Drug Demand
The increasing incidence of hematologic malignancies globally is significantly influencing the multiple myeloma drug market. In 2022, these cancers accounted for 6.6% of all diagnosed cancer cases and 7.2% of related deaths, underscoring the critical need for targeted therapies. As multiple myeloma stems largely from genetic abnormalities, its treatment requires a multidisciplinary approach involving immunomodulatory drugs, chemotherapy, radiation, and stem cell transplants. Platelet transfusions also play a role in managing side effects. With early detection improving, more patients are eligible for advanced treatments. Healthcare systems worldwide are under pressure to offer effective therapeutics, which is accelerating innovation and boosting investments in myeloma-specific drugs, thus contributing to the positive multiple myeloma drugs market outlook.
Technological Advancements Accelerating Treatment Innovations
Technological progress is transforming multiple myeloma treatment, particularly through innovations like microRNA-based therapies and nanomedicines. These platforms enable precision targeting of malignant cells while minimizing damage to healthy tissues. A prime example is Ardena's nanomedicine facility in Oss, Netherlands, which secured GMP certification in November 2024 after a €20 million investment. This facility supports complex manufacturing of lipid and polymeric nanoparticles, delivery vehicles critical for transporting macromolecular agents to the bone marrow and triggering antitumor responses. Such innovations not only enhance treatment outcomes but also lower long-term healthcare costs by reducing complications. As pharmaceutical companies expand their nanotech capabilities, these developments are expected to play a vital role in driving the multiple myeloma drug market growth.
Increasing Biologic Therapy Adoption and Healthcare Spending
Growing awareness about biologic therapies is reshaping treatment preferences in the multiple myeloma landscape. These drugs leverage the immune system to recognize and eliminate cancer cells, offering a less invasive and often more effective alternative to conventional treatments. Patients are increasingly drawn to therapies that provide targeted mechanisms with fewer systemic side effects. Alongside this trend, rising global healthcare expenditures, reported at USD 9.8 Trillion in 2021, equating to 10.3% of global GDP, are enabling wider access to these advanced treatments. Combined with the pharmaceutical industry's expanding research budgets, biologic therapies are gaining traction across developed and emerging markets. This shift is expected to significantly contribute to the expansion of the multiple myeloma drug market in the coming years.
Targeted therapy plays a pivotal role in the multiple myeloma drug market by offering a precision-based approach that directly interferes with specific molecules responsible for cancer cell growth and survival. These therapies, such as proteasome inhibitors and histone deacetylase inhibitors, provide enhanced efficacy with fewer side effects compared to traditional treatments. The increasing understanding of the genetic and molecular mechanisms of multiple myeloma has led to the development of more selective drugs. Ongoing clinical trials and regulatory approvals are further accelerating adoption. Moreover, the ability of targeted therapy to be used in combination regimens is expanding its clinical utility, driving consistent growth in this segment globally.
Biologic therapy has gained significant prominence in the multiple myeloma drug market, largely due to its ability to harness the body's immune system to combat cancer. Monoclonal antibodies, such as daratumumab and elotuzumab, have shown strong clinical success by targeting specific proteins on myeloma cells. The increasing acceptance of immunotherapy approaches and the growing demand for personalized medicine are key growth drivers for this segment. With rising awareness among healthcare providers and patients regarding the benefits of biologics, coupled with supportive reimbursement frameworks and expanding biologics pipelines, the segment is expected to experience sustained growth in both developed and emerging markets.
Chemotherapy continues to serve as a foundational component in the treatment of multiple myeloma, particularly in combination with other therapeutic classes. Although its prominence has somewhat declined with the emergence of targeted and biologic therapies, chemotherapy remains essential, especially in newly diagnosed or relapsed patients requiring rapid cytoreduction. The wide availability, proven efficacy, and cost-effectiveness of chemotherapeutic agents ensure their continued use. Advancements in formulation, including oral chemotherapies and supportive care options to manage side effects, have also contributed to maintaining its relevance. As part of combination regimens, chemotherapy enhances overall treatment outcomes, securing its ongoing role in the evolving multiple myeloma drug market.
Immunomodulatory drugs stand as the largest drug type in 2024, holding around 38.7% of the market. The immunomodulatory drugs segment dominates the multiple myeloma drug market due to its proven effectiveness in enhancing immune responses and directly targeting cancer cells. These drugs, such as lenalidomide and pomalidomide, have become foundational therapies for both newly diagnosed and relapsed patients, often used in combination with other treatments like corticosteroids and proteasome inhibitors. Their ability to modulate the tumor microenvironment, suppress abnormal plasma cells, and improve patient outcomes has led to widespread adoption. Additionally, ongoing clinical trials and regulatory approvals continue to expand their indications, reinforcing their central role in treatment protocols and sustaining their dominance in the multiple myeloma drug market.
Men represent a significant segment in the multiple myeloma drug market, accounting for a higher prevalence rate compared to women. Epidemiological data indicate that men are more frequently diagnosed with multiple myeloma, which naturally drives greater demand for therapeutic interventions among this demographic. The higher incidence may be attributed to genetic, hormonal, and lifestyle factors, including greater exposure to environmental risk elements such as industrial chemicals and tobacco use. As a result, pharmaceutical companies and healthcare providers often prioritize this patient group in clinical trials and treatment planning. Increased health awareness, along with access to advanced diagnostics and treatment options, further supports the growth of this segment within the market.
Women constitute an essential and growing segment in the multiple myeloma drug market, supported by rising awareness and improving access to healthcare. Though the prevalence of multiple myeloma is relatively lower among women compared to men, the market demand from this group is expanding due to early diagnosis and increasing participation in screening programs. Advances in gender-specific research and the growing focus on tailoring therapies to address women's physiological responses contribute to better treatment outcomes. Additionally, supportive care services and educational initiatives have improved adherence to treatment regimens among female patients, fueling continued market growth in this segment.
Hospital pharmacies lead the market with around 57.0% of market share in 2024. The hospital pharmacies segment dominates the multiple myeloma drug market due to the complex nature of treatment regimens and the need for specialized administration and monitoring. Multiple myeloma therapies often involve intravenous drugs, combination treatments, and biologics that require hospital-grade infrastructure and professional supervision. Hospitals serve as primary points for cancer diagnosis, staging, and early treatment, making them central to drug dispensing and patient management. Furthermore, hospital pharmacies maintain a broader inventory of high-cost and high-risk oncology drugs, ensuring immediate access for patients undergoing intensive therapies. This central role in comprehensive cancer care reinforces their dominance in the multiple myeloma drug market.
In 2024, North America accounted for the largest market share of over 40.7%. North America dominates the multiple myeloma drug market due to its advanced healthcare infrastructure, high healthcare spending, and robust presence of leading pharmaceutical companies engaged in oncology research. The region benefits from early adoption of innovative therapies, strong regulatory support from agencies like the FDA, and widespread access to cutting-edge treatments. A high prevalence of multiple myeloma, combined with increased awareness and early diagnosis, contributes to the growing demand for targeted and biologic therapies. Additionally, favorable reimbursement policies and significant investment in clinical trials further strengthen North America's leadership in this space, ensuring its continued prominence in the multiple myeloma drug market. For instance, in June 2024, AbbVie begun its Phase III CERVINO trial for ABBV-383, a bispecific T-cell engager targeting BCMA and CD3, in patients with relapsed/refractory multiple myeloma. The global, randomized trial will enroll 380 patients who have had at least two prior therapies but not BCMA-targeted ones. Participants will receive ABBV-383 or standard available therapies. The primary endpoints are progression-free survival and overall response rate, with secondary measures including survival and disease symptom changes. ABBV-383 is dosed monthly to simplify treatment.
United States Multiple Myeloma Drugs Market Analysis
In 2024, the United States held a market share of over 86.8% in North America. The United States multiple myeloma drug market is primarily driven by the rising incidence of the disease, supported by improved diagnostic techniques that enable earlier detection and intervention. In 2025, the American Cancer Society projected approximately 36,110 new cases of multiple myeloma in the U.S. (20,030 in men, 16,080 in women) and about 12,030 related deaths (6,540 in men, 5,490 in women). In accordance with this, robust advancements in immunotherapy and precision medicine are fostering the development of novel drug classes and combination regimens, thereby impelling the market. The growing presence of a robust clinical trial pipeline, pushed by industry-academic collaborations, is further propelling market growth. Similarly, the growing awareness among healthcare providers and patients regarding early treatment options is enhancing adoption rates. Additionally, the market is benefiting from strategic mergers, acquisitions, and partnerships that strengthen research capabilities and expand portfolios. Apart from this, continued investments in biomarker-driven research and personalized medicine are driving targeted drug development and market expansion.
Europe Multiple Myeloma Drugs Market Analysis
The multiple myeloma drug market in Europe is experiencing growth due to the region's aging population, which elevates the prevalence of hematologic cancers requiring advanced treatments. It has been reported that Europe's median age is projected to rise by 5.5 years, from 44.7 in 2024 to 50.2 in 2100, with the share of people aged 80 and above expected to grow from 6.1% to 15.3%. In line with this, continued improvements in healthcare infrastructure across Europe are enhancing market accessibility. Similarly, the expansion of national cancer control programs, which promote earlier detection and the establishment of structured care pathways, is fostering market expansion. The increase in government funding dedicated to research on rare and complex diseases is driving pharmaceutical innovation. Additionally, the increasing acceptance of biosimilars is reducing treatment costs and expanding patient access to these therapies. Furthermore, the growing integration of digital health tools and electronic medical records, which improves personalized treatment planning and monitoring, is stimulating market appeal. Besides this, cross-border healthcare collaboration within the EU is strengthening knowledge exchange and accelerating the adoption of advanced multiple myeloma therapies across member states.
Asia Pacific Multiple Myeloma Drugss Market Analysis
The Asia Pacific market is largely driven by rising healthcare spending in emerging economies, which strengthens access to advanced oncology therapies. An industry report projected that India's healthcare spending will increase from 3.3% to 5% of GDP by 2030. Furthermore, rapid urbanization and changing lifestyles are increasing cancer prevalence, thereby strengthening market demand. The strong government initiatives to raise awareness of rare diseases and improve patient registries, which support early diagnosis and timely care, are bolstering market development. Additionally, strategic collaborations between regional biotech companies and global pharmaceutical firms are accelerating the transfer of technology and innovative drug development. The expansion of specialized cancer treatment centers and the growth of medical tourism infrastructure are attracting patients seeking advanced therapies. As such, India's medical tourism sector is expected to grow at a double-digit rate of 14-15% following the recent relaxation of visa rules outlined in the Union Budget 2025-26. Moreover, broader reimbursement coverage and regulatory reforms across key Asia-Pacific countries are facilitating the faster approval and availability of cutting-edge multiple myeloma treatments, thereby providing an impetus to the market.
Latin America Multiple Myeloma Drugss Market Analysis
In Latin America, the multiple myeloma drug market is growing due to the steady improvement of healthcare systems and greater public funding for oncology services across the region. Accordingly, by March 2025, Brazil's radiotherapy expansion plan, with Varian, added 92 linacs and nine HDR afterloaders, reducing wait times and enabling advanced treatments. The initiative now treats an estimated 55,000 cancer patients annually, expanding access nationwide. In addition to this, rising awareness initiatives and patient advocacy programs are encouraging earlier diagnosis and improved treatment uptake. The increasing presence of multinational pharmaceutical companies, through the formation of strategic partnerships and expansion of distribution channels, is bolstering market development. Furthermore, wider participation in international clinical trials is fostering scientific exchange and supporting faster access to advanced multiple myeloma therapies, thereby creating lucrative market opportunities.
Middle East and Africa Multiple Myeloma Drugs Market Analysis
The market in the Middle East and Africa is significantly influenced by rising healthcare expenditure and strong government initiatives to modernize oncology care. Industry analysis indicates that the UAE's healthcare spending ranks among the highest per capita globally, at approximately USD 1,200. The sector generates over USD 4.63 Billion in annual revenue and comprises 75 insurers, which provide more than 12,000 policies. Similarly, the continual development of regional cancer centers is expanding access to specialized diagnostics and advanced treatment options for multiple myeloma. Furthermore, increasing collaborations between local healthcare systems and global pharmaceutical companies are enhancing the market reach. Similarly, the growth of public-private partnerships and focused investments in training medical professionals is strengthening the oncology workforce, ensuring that patients receive high-quality, up-to-date care and improving overall treatment outcomes.
The competitive landscape of the multiple myeloma drug market is characterized by intense R&D activity, strategic collaborations, and continuous drug innovation. Leading players are focusing on expanding their product pipelines through the development of advanced biologics, immunotherapies, and targeted treatments. For instance, in June 2025, Glenmark's subsidiary, Ichnos Glenmark Innovation (IGI), reported promising early trial results for its cancer drug ISB 2001, targeting relapsed/refractory multiple myeloma. The novel trispecific antibody therapy showed a 79% overall response rate (ORR) among heavily pretreated patients, with 30% achieving complete or near-complete response. Six of eight patients tested negative for minimal residual disease. The trial, presented at ASCO 2025, showed manageable side effects and is moving into dose expansion to determine optimal dosing for broader testing. Regulatory approvals and fast-track designations are accelerating the launch of novel therapeutics, while mergers and licensing agreements are enhancing global reach and capabilities. Companies are increasingly investing in technologies such as CAR-T cell therapies and nanomedicine-based delivery systems to gain a competitive edge. With rising competition and robust clinical pipelines, the multiple myeloma drugs market forecast projects sustained innovation and market expansion through 2033, driven by unmet medical needs and a growing patient population worldwide.